title: Beta-2 adrenergic responses to tulobuterol in airway smooth muscle, vascular smooth muscle and adrenergic nerves.
abstract: Experiments were designed to determine the mechanism of action of the bronchodilator drug tulobuterol. Tissues were suspended in organ chambers for isometric tension recording. Tulobuterol caused concentration-dependent relaxations of guinea pig tracheae, canine saphenous veins and canine bronchi; the compound relaxed canine coronary arteries only at high concentrations and did not affect spontaneously beating guinea pig atria. A metabolite of tulobuterol, 4-hydroxytulobuterol, was more potent in relaxing guinea pig tracheae than tulobuterol, salbutamol and isoproterenol. Other metabolites (3-hydroxy-, 5-hydroxy- and 4,5-dihydroxytulobuterol) were less efficacious than 4-hydroxytulobuterol. Both tulobuterol and 4-hydroxytulobuterol acted as partial agonists. The effects of tulobuterol in the saphenous vein (but not in the coronary artery) were antagonized by the selective beta-2 adrenergic blocker ICI 118,551 but were not affected by the selective beta-1 adrenergic inhibitor metoprolol. In bronchi, removal of the epithelium reduced the relaxations caused by tulobuterol. The drug did not inhibit responses of canine bronchi to electrical stimulation of the cholinergic nerves more than those to exogenous acetylcholine. Tulobuterol caused a moderate augmentation of the evoked release of [3H]norepinephrine in canine saphenous veins previously incubated with the labeled transmitter. Thus, tulobuterol is a selective beta-2 adrenergic agonist with minimal nonselective inhibitory effect on airway and vascular smooth muscle. It also facilitates adrenergic neurotransmission, which may help to explain its bronchodilator effect in the intact organism. Tulobuterol does not activate beta-1 adrenoceptors and has no direct positive chronotropic effect. A metabolite of tulobuterol, 4-hydroxytulobuterol, is more active than the parent compound.
authors.affiliation: Department of Physiology and Biophysics, Mayo Clinic, Rochester, Minnesota.
authors.forename: F
authors.initials: F
authors.lastname: Ruff
authors.forename: J F
authors.initials: JF
authors.lastname: Zander
authors.forename: Y
authors.initials: Y
authors.lastname: Edoute
authors.forename: M C
authors.initials: MC
authors.lastname: Santais
authors.forename: N A
authors.initials: NA
authors.lastname: Flavahan
authors.forename: T J
authors.initials: TJ
authors.lastname: Verbeuren
authors.forename: P M
authors.initials: PM
authors.lastname: Vanhoutte
mesh_terms: D000320:Adrenergic Fibers / Q000187:drug effects*; D000818:Animals; D001980:Bronchi / Q000187:drug effects; D003331:Coronary Vessels / Q000187:drug effects; D004285:Dogs; D006168:Guinea Pigs; D006325:Heart Atria / Q000187:drug effects; D008790:Metoprolol / Q000494:pharmacology; D009130:Muscle, Smooth / Q000187:drug effects*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D011412:Propanolamines / Q000494:pharmacology; D011943:Receptors, Adrenergic, beta / Q000187:drug effects*; D012501:Saphenous Vein / Q000187:drug effects; D013726:Terbutaline / Q000031:analogs & derivatives* / Q000494:pharmacology; D014132:Trachea / Q000187:drug effects
chemical_list: D011412:Propanolamines; D011943:Receptors, Adrenergic, beta; C026777:ICI 118551; C010809:tulobuterol; D008790:Metoprolol; D013726:Terbutaline